The thymus plays a critical role in adaptive immunity as the site of mature T cell production ([@bib36]). The thymus grows rapidly during early life, generating a large T cell repertoire. It then enters an involution process, leading to decreased production of naive T cells, resulting in impaired immune function in the elderly and preventing complete reconstitution of the immune system in various pathologies ([@bib5]; [@bib45]; [@bib10]). The mechanisms controlling thymic involution are poorly understood, hampering the development of therapeutic strategies to enhance immune function in a wide variety of patients ([@bib39]; [@bib49]).

Although the thymus is composed mostly of T lymphocytes, T cell development requires a complex microenvironment including endothelial, dendritic, and thymic epithelial cells (TECs; [@bib35]). TECs are highly proliferative during thymic expansion, and then their cell cycle slows considerably ([@bib25]; [@bib3]; [@bib35]). Recent data show that keratinocyte growth factor (KGF; or FGF-7) and growth hormone treatment in aged rodents and humans leads to transient thymic expansion and increased production of naive T cells ([@bib37]; [@bib39]). In particular, increased TEC numbers were observed upon KGF treatment ([@bib37]; [@bib47]). IL-22 also can support thymic regeneration in mice after radiation treatment ([@bib20]). These data suggest that increased numbers of TECs can enhance, at least temporarily, thymic function. Nevertheless, the molecular mechanisms regulating cell cycle activity in TECs are still poorly characterized, and no strategies have been devised yet for long-term thymic growth.

Through its ability to bind the E2F transcription factors, the RB family of proteins (RB, p107, and p130) plays a major role in the control of cell cycle progression. Growth factors and external signals activate Cyclin and Cyclin-dependent kinase (CDK) protein complexes. Upon activation, Cyclin--CDK complexes phosphorylate RB family proteins, resulting in their inactivation. Inactivation of RB family proteins by phosphorylation activates E2F, thereby promoting transcription of genes involved in the G1/S transition of the cell cycle ([@bib27]; [@bib14])

There is no reported thymic phenotype in mice in which any one of the *Rb* family gene is inactivated, possibly because of the strong functional overlap between the three proteins ([@bib17]). Nevertheless, emerging evidence suggests that some members of the RB pathway may play a role in thymic biology, including E2F2, Cyclin D1 (CCND1), p18^Ink4c^, and p27^Kip1^ ([@bib44]; [@bib21]; [@bib43]; [@bib31]; [@bib46]; [@bib28]; [@bib50]; [@bib13]). However, the mechanisms underlying how the cell cycle machinery affects thymus development and involution are still unknown.

Here we report that deletion of *Rb* family genes in the thymus of mice leads to increased proliferation in TEC populations and prevents thymic involution. Furthermore, we found that the RB family regulates the transcription of *Foxn1*, an important regulator of TEC differentiation and function. Finally, we demonstrate that the increased expression of *Foxn1* is required for the thymus expansion observed in *Rb* family mutant mice. These data identify a new RB-E2F-Foxn1 module as a critical regulator of thymic involution and function.

RESULTS AND DISCUSSION
======================

We previously reported that inactivation of the entire *Rb* gene family in young adult mice (3--6-wk-old *Mx1-Cre Rb^lox/lox^; p130^lox/lox^; p107^−/−^* mice) results in rapid death as the result of hyperproliferation in multiple organs ([@bib57]; [@bib11]). In contrast, reintroduction of one copy of *p107* (*Mx1-Cre Rb^lox/lox^; p130^lox/lox^; p107^+/−^* or *Mx1-Cre p107-Single* mice) rescues the lethality of the triple knockout mice and significantly extends their lifespan up to 9--12 mo of age ([@bib57], [@bib58]). At that age, although *p107-Single* mice that lack Cre-recombinase are still healthy, *Mx1-Cre p107-Single* mice exhibit weight loss and respiratory distress. Upon autopsy, we found that the thymus of *Mx1-Cre p107-Single* mice was significantly increased in size ([Fig. 1 A](#fig1){ref-type="fig"}, left), compressing the lungs. This thymic growth correlated with increased cellularity ([Fig. 1 B](#fig1){ref-type="fig"}). The plateau observed after several months of continuous growth in mutant mice may be the result of mechanical or vascular constraints, limits of the BM to generate T cell precursors, or a thymus-intrinsic effect.

![**Thymic growth and increased T cells in *Mx1-Cre p107-Single* mice (*Mx1-Cre Rb^lox/lox^; p130^lox/lox^; p107^+/−^*).** (A, left) Representative control (Ctrl; top) and mutant (Mut; bottom) thymi (dashed lines). (right) H&E staining of representative control (top) and mutant (bottom) thymi. (B) Thymic cellularity (×10^7^, log2 scale) of control and *Mx1-Cre p107-Single* mice after inactivation of the *Rb* family in young mice (*n* = 3 for each time point; asterisks indicate P \< 0.05; ns indicates no significant difference; p-values: 3 wk = 0.35, 3 mo = 0.018, 5 mo = 0.04, and 7 mo = 0.03). Horizontal bars indicate the mean. (C) Comparison of thymic cellularity between control and *Mx1-Cre Rb/p130* mutant mice at 3 wk (Ctrl: 29 ± 9.5 × 10^8^ cells; *Mx1-Cre Rb/p130*: 38 ± 24.6 × 10^8^ cells; P = 0.59; *n* = 3) and 16 wk (Ctrl: 7.6 ± 1.4 × 10^8^ cells; *Mx1-Cre Rb/p130*: 10.8 ± 7.4 × 10^8^ cells; P = 0.49; *n* = 3). (D) Oil Red O staining (red) on sections from 2-wk-old control (left), 9-mo-old control (middle), and 9-mo-old *Mx1-Cre p107-Single* mutant (right) thymi (performed on three mice each). Bars: (A) 200 µm; (D) 100 µm. (E) Quantification of intrathymic T cell progenitor populations between control and mutant mice (*n* = 3). Lineage-negative populations include CD25^−^ cKit^−^ (Ctrl: 48.65 ± 8.27%; Mut: 42.07 ± 12.95%; P = 0.54), CD25^+^ cKit^−^ (Ctrl: 44.75 ± 2.90%; Mut: 53.37 ± 11.49%; P = 0.42), CD25^−^ cKit^+^ (Ctrl: 3.08 ± 3.7%; Mut: 1.65 ± 1.64%; P = 0.45), and CD25^+^ cKit^+^ (Ctrl: 3.28 ± 1.28%; Mut: 2.65 ± 0.69%; P = 0.60). (F) Quantification of DN (Ctrl: 22.60 ± 0.82%; Mut: 17.33 ± 4.43%; P = 0.08), DP (Ctrl: 59.73 ± 3.98%; Mut: 73.61 ± 5.43%; P = 0.004), CD4^+^ T cell (Ctrl: 8.67 ± 0.83%; Mut: 5.00 ± 2.51%; P = 0.04), and CD8^+^ T cell populations (Ctrl: 8.93 ± 2.96%; Mut: 4.98 ± 1.91%; P = 0.03). (G) T cell BrdU incorporation 1 h after injection was quantified by FACS analysis (*n* = 3; p-values: Total = 0.002, DN = 0.14, DP = 0.05, CD4^+^ = 0.24, and CD8^+^ = 0.22). (H) Quantification of splenic naive T cells in mutants and control mice (*n* = 3 each; CD4^+^: Ctrl, 42.76 ± 5.81%; Mut, 55.06 ± 5.42% \[P = 0.05\]; CD8^+^: Ctrl, 50.14 ± 5.32%; Mut, 66.24 ± 3.64% \[P = 0.03\]). All error bars indicate standard error.](JEM_20121716_Fig1){#fig1}

Histopathological analysis showed no gross alteration of the thymic architecture in mutant mice compared with controls ([Fig. 1 A](#fig1){ref-type="fig"}, right). As expected ([@bib62]; [@bib3]), the thymus from 6--9-mo-old mice accumulated lipids, as indicated by Oil Red O staining. In contrast, the thymus of young control (2--3 mo of age) and old mutant mice (6--9 mo of age) showed little lipid accumulation ([Fig. 1 D](#fig1){ref-type="fig"}). The only defect we detected in mutant mice outside of the thymus was epidermal hyperplasia (not depicted; previously described in [@bib48]). Thymic size in *Mx1-Cre Rb/p130* double mutant mice was indistinguishable from that of control mice ([Fig. 1 D](#fig1){ref-type="fig"}). Overall, these data show that loss of RB family function in *Mx1-Cre p107-Single* mice results in the expansion of the thymus, while preserving overall thymic architecture.

Flow cytometry analysis of progenitor thymocyte populations ([Fig. 1 E](#fig1){ref-type="fig"} and [Fig. S1 A](http://www.jem.org/cgi/content/full/jem.20121716/DC1){#supp1}) revealed no significant differences in the frequency of these cell populations in the thymus of control and mutant mice. There were no significant changes in the number of double-negative (DN) cells between control and mutant mice. Double-positive (DP) mature intrathymic T cells were slightly more numerous in the mutant mice, whereas CD4^+^ and CD8^+^ populations were smaller ([Fig. 1 F](#fig1){ref-type="fig"} and Fig. S1 B). These changes may reflect a higher percentage of DP thymocytes failing positive selection in the mutant animals ([@bib38]). As expected ([@bib42]), BrdU/propidium iodide (PI) cell cycle analysis showed some BrdU incorporation in CD4^+^ and CD8^+^ populations in control mice, but proliferation rates were higher in mutant CD4^+^ and CD8^+^ cells ([Fig. 1 G](#fig1){ref-type="fig"}). These observations show that loss of RB family function results in a general expansion of thymocytes rather than expansion of a specific subpopulation as would be seen in a T cell lymphoma. Notably, this increase in the number of intrathymic T cells was accompanied by an increase in the number of peripheral CD62L^+^ CD44^−^ naive T cells in *Rb* family mutant mice ([Fig. 1 H](#fig1){ref-type="fig"} and Fig. S1 C). This last finding is consistent with a recent observation that forced expression of thymic *Foxn1* leads to a decrease in peripheral memory T cells ([@bib63]). Thus, inactivation of the *Rb* gene family results in a thymic expansion that correlates with increased production of naive T cells in mice.

To investigate the origin of thymic expansion in *Mx1-Cre p107-Single* mice, we generated chimeric mice by transplanting Ly5.1^+^/ Ly5.2^+^ wild-type BM cells into 3-mo-old Ly5.1^+^ lethally irradiated mutant or control mice ([Fig. 2 A](#fig2){ref-type="fig"}). Upon reconstitution of hematopoiesis, chimeric mice were injected with polyinosine:polycytosine (pI:pC). 3 mo later, the thymi of *Mx1-Cre p107-Single* mice reconstituted with wild-type hematopoietic cells were enlarged significantly compared with the thymi from chimeric wild-type/control mice ([Fig. 2 B](#fig2){ref-type="fig"}). In both cases, as expected, BM cells and thymocytes from chimeric mutant and control mice expressed both Ly5.1 and Ly5.2 isoforms, confirming their wild-type origin ([Fig. 2 C](#fig2){ref-type="fig"}). Although all T cell populations were expanded in chimeric mutant mice ([Fig. 2 D](#fig2){ref-type="fig"}), there was, overall, no significant difference in the proportional representation of DN, DP, CD4^+^, and CD8^+^ populations between wild-type and mutant chimeric mice ([Fig. 2 E](#fig2){ref-type="fig"}). Nevertheless, the proliferative index of T cell populations in mutant mice was increased compared with controls ([Fig. 2 E](#fig2){ref-type="fig"}). Mutant T cells failed to exhibit increased proliferation upon transplantation of mutant BM cells in recipient mice (not depicted). Thus, although there may be a contribution of increased T cell proliferation to the thymic expansion observed in mutant mice, the thymus expansion observed in *Rb* family mutant mice does not depend on the deletion of *Rb* family genes in BM-derived cells.

![**The thymic expansion in *Rb* family mutant mice does not originate from the hematopoietic compartment.** (A) Control (Ctrl) and *Mx1-Cre p107-Single* (Mut) mice expressing the Ly5.1 surface marker were lethally irradiated and transplanted with BM from Ly5.1/Ly5.2 wild-type mice. (B) Thymic cellularity (×10^8^) of control and *Mx1-Cre p107-Single* chimeric mice (*n* = 5; P = 0.02). (C) Quantified (Ctrl: 95.23 ± 2.2% donor-derived; Mut: 97 ± 1.01% donor-derived; P = 0.19; *n* = 3). (D) Quantification of T cells in control and mutant chimeric mice (DN: Ctrl, 8.54 ± 2.44%; Mut, 11.88 ± 7.33% \[P = 0.42\]; DP: Ctrl, 80.68 ± 3.75%; Mut, 71.98 ± 5.87% \[P = 0.046\]; CD4^+^: Ctrl, 7.2 ± 1.26%; Mut, 10.74 ± 3.5% \[P = 0.11\]; CD8^+^: Ctrl, 3.59 ± 0.76%; Mut, 5.35 ± 1.87% \[P = 0.13%\]; *n* = 3). (E) PI analysis of cell cycle activity in control and mutant chimeric mice (G1: Ctrl, 80.65 ± 2.02%; Mut, 70.53 ± 1.13% \[P = 0.0001\]; S: Ctrl, 3.93 ± 0.16%; Mut, 5.00 ± 0.66% \[P = 0.02\]; G2: Ctrl, 15.30 ± 1.85%; Mut, 24.5 ± 5.40% \[P = 0.0001\]; *n* = 4). (F) Cytokine and receptor expression in thymic extracts from control and mutant mice after lethal irradiation and rescue with wild-type BM as assayed by RT-qPCR (p-values: *Il7* = 0.41, *Scf* = 0.37, *Fgfr2b* = 0.58, *Wnt4* = 0.97, and *Dll4* = 0.64; *n* = 3). Asterisks indicate P \< 0.05; ns indicates no significant difference. All error bars indicate standard error.](JEM_20121716R_Fig2){#fig2}

Because thymic stroma-derived cytokines and growth factors are important for thymus growth and T cell proliferation and differentiation, we assessed mRNA expression levels for several cytokines and receptors produced in the thymus (*Il7*, *Scf/kitl*, *Fgfr2b*, *Wnt4*, and *Dll4*). After normalization to *Eva1* levels ([@bib26]; [@bib18]; [@bib37]), we found no significant difference in per-cell levels of these mRNAs between chimeric mutant and chimeric control groups ([Fig. 2 F](#fig2){ref-type="fig"}). These data provide more evidence that the thymic milieu is essentially normal in the enlarged thymus of *Mx1-Cre p107-Single* mice, further suggesting that the thymic microenvironment is expanded and maintained in *Rb* family mutant mice.

TECs are a critical component of the thymic microenvironment, providing many of the functions needed to control T cell differentiation and selection. Thus, we asked whether TECs may be responsible for the thymus phenotype observed in *Mx1-Cre p107-Single* mutant mice. We found that the pool of phosphorylated RB decreased with age, correlating with higher levels of CCND1 in TECs from younger mice; Cdk4 levels did not change with age ([Fig. 3 A](#fig3){ref-type="fig"}). Accordingly, transcription of canonical E2F targets in TECs significantly decreased with age ([Fig. 3 C](#fig3){ref-type="fig"}), further correlating thymic involution with increased RB activity. We also confirmed loss of RB by immunoblot analysis ([Fig. 3 A](#fig3){ref-type="fig"}) and deletion of *Rb* and *p130* by PCR in injected and noninjected *Mx1-Cre p107-Single* TECs ([Fig. 3 B](#fig3){ref-type="fig"}). Deletion of *Rb* and *p130* without pI:pC injections confirms that the *Mx1* promoter can be induced by endogenous signals ([@bib32]); this deletion in noninduced mice also led to a significant increase in thymus size (thymic cellularity in control, 9.8 ± 0.2 × 10^7^, versus noninjected *Mx1-Cre p107-Single*, 1.2 ± 0.7 × 10^9^; P = 0.0001). The extent of deletion of the *Rb* family seen in the thymus of these noninduced mice suggests that the mutant cells may outcompete wild-type or partially deleted cells as the thymus becomes enlarged. Notably, inactivation of the *Rb* gene family in *Mx1-Cre p107-Single* mice prevented the down-regulation of E2F targets normally observed during aging ([Fig. 3 D](#fig3){ref-type="fig"}). Because CCND1 production is induced by mitogenic signals ([@bib30]), the lack of detectable CCND1 in 15-wk-old control and mutant mice argues that, at this age, TECs do not receive extracellular mitogenic signals, further suggesting that the thymic growth observed in *Mx1-Cre p107-Single* mice is caused by a TEC-intrinsic effect.

![**Expansion of functional TECs in the thymus of *Rb* family mutant mice.** (A) Immunoblot analysis (one of two replicates shown) of protein lysates from pooled CD45^−^ EPCAM^+^ MHCII^+^ TECs from young (2 wk; *n* = 10), control (Ctrl; 15 wk injected; *n* = 10), and *Mx1-Cre p107-single* (15 wk; *n* = 3 injected, 2 noninjected) thymi against RB, phospho-RB, CCND1, CDK4, and α-Tubulin (loading control). (D) PCR analysis of genomic DNA isolated from CD45^−^ EPCAM^+^ MHCII^+^ TECs for the lox-flanked or Cre-deleted exons of *Rb* and *p130* in 15-wk-old control, non--pI:pC-injected *Mx1-Cre p107-Single*, and pI:pC-injected *Mx1-Cre p107-Single* mice (one of four shown). (C) RT-qPCR evaluation of expression of E2F target and S-phase genes in flow-purified TECs from 2-wk-old (*n* = 2), 3-wk-old (*n* = 5), and 15-wk-old control mice (*n* = 3), including *E2f1* (p-values for all genes presented as 2--3 wk and 3--15 wk, P = 0.044 and 0.031, respectively), *p107* (P = 0.001 and 0.04), *PCNA* (P = 0.026 and 0.018), *bMyb* (P = 0.026 and 0.041), *Ezh2* (P = 0.0001 and 0.40), and *Mcm3* (P = 0.018 and 0.073). (D) RT-qPCR evaluation of expression of E2F target and S-phase genes in flow-purified TECs from control and mutant TECs (15 wk; *n* = 3 each). Genes analyzed included *E2f1* (P = 0.017), *p107* (P = 0.004), *PCNA* (P = 0.033), *bMyb* (P = 0.026), *Ezh2* (P = 0.059), and *Mcm3* (P = 0.022). (E) PI analysis of cell cycle activity in TECs from 15-wk-old control and *Mx1-Cre p107-Single* mice (G1: Ctrl, 98.08 ± 1.18%; Mut, 69.17 ± 9.49% \[P = 0.0003\]; S: Ctrl, 1.21 ± 0.78%; Mut, 18.86 ± 6.32% \[P = 0.0002\]; G2: Ctrl, 1.24 ± 0.85%; Mut, 12.13 ± 3.68% \[P = 0.0004\]; *n* = 10 control and 4 mutant). (F) BrdU incorporation into mTECs and cTECs in mutant mice (mTEC: 8.95 ± 5.11%; cTEC: 11.7 ± 3.11%; P = 0.54; *n* = 2). (G) PI analysis of cell cycle activity in mTECs and cTECs from mutant mice (G1: mTEC, 84.17 ± 1.82%; cTEC, 82.4 ± 7.49% \[P = 0.70\]; S: mTEC, 10.63 ± 0.67%; cTEC, 9.30 ± 3.52% \[P = 0.55\]; G2: mTEC, 4.84 ± 1.25%; cTEC, 8.11 ± 3.88% \[P = 0.02\]; *n* = 2). (H) Expression levels of the mTEC-expressed gene, *Aire*, assessed by RT-qPCR in control and mutant thymic extracts, normalized for cell number by *Eva1* levels (*n* = 4; P = 0.58). (I) Quantification of maturing cTEC subpopulations as identified by CD40 and CD205 expression (CD40^−^ CD205^−^: Ctrl, 2.01 ± 0.44%; Mut, 1.89 ± 0.08% \[P = 0.91\]; CD40^+^ CD205^−^: Ctrl, 6.59 ± 4.00%; Mut, 7.23 ± 5.23% \[P = 0.62\]; CD40^−^ CD205^+^: Ctrl, 9.61 ± 1.54%; Mut, 10.06 ± 0.96% \[P = 0.79\]; CD40^+^ CD205^+^: Ctrl, 81.77 ± 5.17%; Mut, 81.14 ± 2.11% \[P = 0.65\]; *n* = 3). (J) Quantification of maturing mTEC subpopulations as identified by CD80 and UEA1 staining (CD80^−^ UEA1^+^: Ctrl, 27.34 ± 2.67%; Mut, 27.35 ± 6.82% \[P = 0.87\]; CD80^+^ UEA1^+^: Ctrl, 51.18 ± 2.84%; Mut, 48.24 ± 8.39% \[P = 0.86\]; *n* = 3). (K) Expression levels of *Il7* and *Scf* assessed by RT-qPCR in control and mutant thymic extracts, normalized by *Eva1* (*n* = 4; p-values: *Il7* = 0.29 and *Scf* = 0.34). (L) Immunofluorescence staining of control (left) and mutant (right) thymi with antibodies for K5 and K8 (top row); β5t, CD31, and PDGFR-β (second row; white arrows indicate blood vessels); K14, UEA1, and DAPI (third row); or K5 and CD205 (bottom row; one of two shown). Bars, 100 µm. Asterisks indicate P \< 0.05; ns indicates no significant difference. All error bars indicate standard error.](JEM_20121716R_Fig3){#fig3}

Next, we sought to quantify the extent to which loss of RB family activity in TECs increased TEC numbers in the mutant thymus. CD45^−^, MHCII^+^ TECs increased 18-fold compared with CD45^+^ hematopoietic cells in the thymus of the mutant mice (control, 0.9 ± 0.49% TECs; mutant, 16.42 ± 6.9% TECs; *n* = 3 each; P = 0.018). Mutant TECs also displayed a higher proliferative index compared with their wild-type counterparts ([Fig. 3 E](#fig3){ref-type="fig"}). Additional separation of CD45^−^ MHCII^+^ TECs from mutant thymus based on the Ly51 surface marker ([@bib60]) showed that mutant cortical TECs (cTECs; Ly51^+^) and medullary TECs (mTECs; Ly51^--^) displayed a high proliferative activity ([Fig. 3, F and G](#fig3){ref-type="fig"}). Compared with Ly51^−^ TECs, we noted an increase in the number of Ly51^+^ TECs in G2, which is sometimes seen in cells with loss of RB function ([@bib54]; [@bib15]).

To determine whether there was a change in proportional representation of particular TEC subsets, we quantified levels of the mature mTEC marker *Aire* ([@bib25]; [@bib19]) in control and mutant thymi. We found no significant difference in *Aire* expression in *Mx1-Cre p107-Single* mice ([Fig. 3 H](#fig3){ref-type="fig"}), suggesting that there is no preferential expansion of either cTECs or mTECs in *Rb* family mutant mice. We also measured by flow cytometry the proportions of cTEC precursors as identified by CD40 and CD205 expression ([@bib52]; [@bib40]). There was no difference in CD40/CD205 subpopulations between control and mutant mice ([Fig. 3 I](#fig3){ref-type="fig"} and Fig. S1 D). Similarly, there were no differences in mTEC precursor populations as measured by CD80 and UEA1 expression ([Fig. 3 J](#fig3){ref-type="fig"} and Fig. S1 E; [@bib1]). When we measured mRNA expression levels for two thymocyte growth cytokines that are expressed by differentiated TECs (*Il7* and *Scf*), we found that the expression levels of these genes on a per-cell basis were not significantly different between control and mutant thymi ([Fig. 3 K](#fig3){ref-type="fig"}). These data support the idea that the major difference between control and *Mx1-Cre p107-Single* mice lies in the number of TECs and not in the differentiation state of these cells.

To examine further the differentiation state of RB family--deficient TECs, we performed immunofluorescence analysis of markers for various cell populations in the thymic microenvironment, including Keratin 5 (K5), Keratin 8 (K8), Keratin 14 (K14), the proteasomal β-5t subunit (β5t), and CD205 ([@bib45]; [@bib53]; [@bib55]). We found no evidence for alteration of thymus structure in mutant mice ([Fig. 3 L](#fig3){ref-type="fig"}). We occasionally observed subcapsular cysts in very large mutant thymi (not depicted), perhaps reflecting the physical limitations placed by the thoracic cavity upon the enlarged thymus. This observation highlights the fact that we performed our analyses of TEC subpopulations at a late time point, when the cells analyzed may represent only the descendants of those cells that initially underwent complete recombination and may have been selected for because of their increased proliferation. Nevertheless, these data indicate that inactivation of the RB family in mice leads to increased TEC proliferation without significantly altering their differentiation.

Thymus organogenesis is coordinated by the successive action of a network of transcription factors ([@bib45]; [@bib34]). We surmised that one mechanism by which loss of RB family function prevents thymic involution might be by maintaining the expression of such factors. However, we found that the expression of *Eya1*, *Pax1*, *Pax9*, *Six1*, *Hoxa3*, and *Tbx1* was similar in control and mutant TECs at 3 mo of age (not depicted). In contrast, *Foxn1* RNA and protein levels were significantly increased in mutant TECs compared with controls ([Fig. 4, A and B](#fig4){ref-type="fig"}). This increase in Foxn1 levels in the mutant thymi may come from increased levels per cell but may also be caused by increased numbers of Foxn1-expressing cells, as suggested by immunofluorescence analysis ([Fig. 4 C](#fig4){ref-type="fig"}). Forced overexpression of Foxn1 was shown to be insufficient to lead to an increase in thymic size ([@bib63]). Thus, the thymic outgrowth in *Rb* family mutant mice is probably also dependent on the increased proliferation seen in mutant TECs, and this increased proliferation is likely to be greater than that with increased Foxn1 levels alone.

![**The RB family controls the expression of *Foxn1*.** (A) Expression of *Foxn1* in CD45^--^ MHCII^+^ TECS from control (Ctrl) and mutant (Mut) mice relative to *Eva1* expression (*n* = 4; P = 0.03). (B) Immunoblot analysis of Foxn1 levels in control and mutant TECs from 12 pooled control and 5 pooled mutant thymi. α-Tubulin is included as a loading control (*n* = 2). (C) Immunofluorescence staining of Foxn1 and CD205 individually and merged (right) in control (top) and mutant (bottom) thymi (one of two shown). Bars, 100 µm. (D) Schematic representation of the *Foxn1* promoter. Region 1a is active in the skin and thymus, whereas region 1b is only active in the skin. (E) Sequence alignment on the UCSC genome browser ([@bib23]) of the promoter region 1a encompassing two E2F sites shows conservation across multiple mammalian species ([@bib29]). Gray highlighting indicates conserved sequences, and black highlighting indicates putative E2F binding sites. (F) Transfection into 210R TECs of an expression plasmid coding for E2F3 together with a luciferase reporter plasmid for either the wild-type region 1a of the *Foxn1* promoter or a region 1a where site 3 has been mutated (*n* = 3; P = 0.03). (G) Transfection into 210R cells of E2F3 and RB expression and the *Foxn1* luciferase reporter plasmid (*n* = 3; P = 0.02). (H) ChIP analysis of E2F3 and E2F4 to sites 1 and 2--3 in TEC100 cells. To adjust for inter-experiment variability of scale of percent input, experiments were normalized to nonspecific antibodies (IgG and anti-p16^INK4a^). This ratio is represented here. In addition, binding to a nonspecific region of the fifth chromosome was included as a negative control (*n* = 3; for site 1 P = 0.02, for site 2--3 P = 0.04). (I) Fold change in percent input as assessed by ChIP analysis of E2F3 and E2F4 binding to the *Foxn1* promoter in TEC100 cells after transient overexpression of RB (*n* = 3 compared with untransfected controls; p-values: E2F3 *Foxn1* site 1 = 0.06 and site 2--3 = 0.04; E2F4 *Foxn1* site 1 = 0.01 and site 2--3 = 0.02). Asterisks indicate P \< 0.05; ns indicates no significant difference. All error bars indicate standard error.](JEM_20121716_Fig4){#fig4}

These observations suggested that, in addition to its canonical role in regulating progression through the cell cycle, the RB family also controls TEC expression of *Foxn1*. Little is known about the transcriptional control of *Foxn1* ([@bib4]). There are two alternate promoters and first exons in the *Foxn1* gene ([@bib51]; [@bib16]): the more distal promoter region (1a) is transcriptionally active in both the skin and the thymus; the second promoter region (1b) is active only in keratinocytes of the skin ([Fig. 4 D](#fig4){ref-type="fig"}). We found by computational analysis that region 1a harbors several conserved putative E2F binding sites. We labeled some of these putative sites "site 1" and "site 2--3", with site 2--3 containing two independent but adjacent putative sites ([Fig. 4 E](#fig4){ref-type="fig"}).

To test the possibility that E2Fs might act at the *Foxn1* promoter, we cotransfected an expression vector coding for E2F3, an activating member of the E2F family, with a reporter plasmid that contains the region 1a of the mouse *Foxn1* promoter upstream of a cDNA coding for the luciferase reporter into the 210R TEC cell line ([@bib22]). We found that E2F3 activated region 1a of the *Foxn1* promoter in this context. A mutation abolishing E2F binding in one of the two sites in site 2--3 partially inhibited the ability of E2F3 to activate the *Foxn1* promoter ([Fig. 4 F](#fig4){ref-type="fig"}). Coexpression of RB markedly inhibited E2F3-mediated activation of the *Foxn1* promoter ([Fig. 4 G](#fig4){ref-type="fig"}). We further tested direct binding of E2Fs to the *Foxn1* promoter by performing chromatin immunoprecipitation (ChIP) experiments in several TEC lines (TEC100, TEC71, and 201R; [@bib22]; [@bib59]). We found that E2F3 and E2F4, a repressor E2F, can bind to both site 1 and site 2--3 but do not bind significantly to regions of nonspecific DNA on the fifth chromosome of the mouse ([Fig. 4 H](#fig4){ref-type="fig"} for TEC100; TEC71 and 210R not depicted). We repeated similar experiments after the transient ectopic expression of RB in TEC100 cells and found a decrease in endogenous *Foxn1* expression (fold change: *Rb* mRNA, 3.1 ± 0.11; *Foxn1* mRNA, −1.8 ± 0.11; *n* = 3 each), as well as a switch between the E2F3 activator and the E2F4 repressor at the *Foxn1* promoter ([Fig. 4 I](#fig4){ref-type="fig"}). Collectively, these data show that *Foxn1* is a direct target of E2F regulation; E2F binds to and controls transcription at the *Foxn1* promoter, and RB inhibits this activation.

To assess the in vivo functional role of increased Foxn1 levels in the thymus expansion observed in *Mx1-Cre p107-Single* mice, we studied thymic growth in *Mx1-Cre p107-Single; Foxn1^LacZ^* mutant mice. *Foxn1^LacZ^* is a hypomorphic allele of *Foxn1*, which causes down-regulation of Foxn1 protein expression from soon after birth; of interest, *Foxn1^LacZ^* heterozygous mice have no appreciable thymic defects ([@bib12]). Similar to *Mx1-Cre p107-Single* mice, *Mx1-Cre p107-Single Foxn1^LacZ/+^* mice displayed significant thymic expansion. In contrast, *Mx1-Cre p107-Single Foxn1^LacZ/LacZ^* mice had a thymus equivalent in size to thymi from control (*Rb^lox/lox^; p130^lox/lox^; p107^+/−^; Foxn1^+/+^* without *Cre*) mice ([Fig. 5, A and B](#fig5){ref-type="fig"}). As expected, Foxn1 levels were reduced in the thymus of *Mx1-Cre p107-Single Foxn1^LacZ/LacZ^* mice compared with *Mx1-Cre p107-Single Foxn1^LacZ/+^* or *Mx1-Cre p107-Single* mice ([Fig. 5, C and D](#fig5){ref-type="fig"}). We also observed decreased expression of E2F targets in the thymus of *Mx1-Cre p107-Single Foxn1^LacZ/LacZ^* mice ([Fig. 5 E](#fig5){ref-type="fig"}). This result suggests, as has been observed in zebrafish ([@bib33]), that Foxn1 plays a role not only in differentiation of TECs but also in promoting proliferation through regulation of S phase genes. These observations also indicate that decreased expression of *Foxn1* is sufficient to rescue the thymic phenotype observed in *Rb* family mutant mice, indicating that increased *Foxn1* levels induced by unrestricted E2F activity upon inactivation of *Rb* family genes are a major cause of the expanding thymus in these mice.

![**Reduction of *Foxn1* levels reverses the enlarged thymus phenotype in *Mx1-Cre p107-Single* mice.** (A) Thymic cellularity in control (Ctrl) and *Rb* family mutant (Mut) mice in the presence and in the absence of the *Foxn1^LacZ^* allele (*n* = 3; P = 0.02). (B) Representative images of whole thymus explants (top) and of H&E-stained sections (bottom; *n* = 5) from mice in A. (C) Representative immunofluorescence analysis of Foxn1 and K5 expression in sections prepared from control and *Rb* family mutant mice in the presence and absence of the *Foxn1^LacZ^* allele (*n* = 2). Bars: (B, top) 500 µm; (B, bottom) 200 µm; (C) 100 µm. (D) Analysis by RT-qPCR of *Foxn1* message level in TECs from *p107-single Foxn1 ^+/+^*, *P107-single Foxn1^Lacz/Lacz^*, *Mx1-Cre p107-single Foxn1^+/+^*, and *Mx1-Cre p107-single Foxn1^LacZ/LacZ^* (*n* = 3, none pI:pC injected; P = 0.023). (E) Evaluation of E2F target and S-phase genes in control, *Mx1-Cre p107-single*, and *Mx1-Cre p107-single Foxn1^LacZ/LacZ^* TECs (*n* = 3; 15 wk). Genes analyzed included *E2f1* (P = 0.031), *p107* (P = 0.008), *PCNA* (P = 0.02), *bMyb* (P = 0.01), *Ezh2* (P = 0.12), and *Mcm3* (P = 0.043). Asterisks indicate P \< 0.05; ns indicates no significant difference. All error bars indicate standard error.](JEM_20121716_Fig5){#fig5}

The transcriptional activation of *Foxn1* in RB family mutant cells is reminiscent of the interactions between RB, E2F, and PPARγ (peroxisome proliferator-activated receptor gamma subunit): increased levels of PPARγ upon loss of RB function in mesenchymal cells change the fate of these cells toward the adipocytic lineage and may affect the spectrum of tumors in mice ([@bib9]). However, a unique aspect of the RB-E2F-Foxn1 module is that it keeps in check the protumorigenic consequences of losing RB family function, at least in part by activating prodifferentiation functions of Foxn1.

Our data demonstrate that the RB pathway plays a key cell-autonomous role in TECs to control maximal thymic size and aging. This result is striking when one considers that thymic size likely is controlled by complex feedback interactions between stromal cells and maturing T cells. Perhaps surprising, given the well-characterized tumor suppressor role of RB family members, loss of RB family function in the thymus does not perturb the differentiation of TECs or T cells and simply increases the proliferation of some of these cells. These observations raise the possibility that loss of RB family function could be used to restore or promote thymic expansion and T cell production in patients ([@bib56]; [@bib61]). Clearly, however, constant inactivation of RB family function in the thymus, although initially beneficial for the immune system of mice, eventually becomes detrimental to the animals when the mutant thymus has reached a large size in the chest. Thus, an important future step will be to identify novel means to transiently inactivate the RB family in a controlled fashion to minimize the potential negative effects of this inactivation while optimizing the benefits to the immune system of patients.

MATERIALS AND METHODS
=====================

### Animals.

All mice where housed in the Stanford University School of Medicine Research Animal Facility in accordance with institutional and National Institutes of Health guidelines. All animal care and experiments were approved by the Stanford University Administrative Panel on Laboratory Animal Care and followed the guidelines of this animal use committee. Mice were of a mixed C57/129 background. *Mx1-Cre Rb^lox/lox^ p130^lox/lox^ p107^−/−^* mice were previously described ([@bib57]). *Mx1-Cre p107-Single* mice were generated by breeding *Mx1-Cre Rb^lox/lox^ p130^lox/lox^ p107^−/−^* mice with *Mx1-Cre Rb^lox/lox^ p130^lox/lox^* mice. The *Foxn1*-*IRES*-*LacZ* transgene was described previously ([@bib12]). These mice were bred through successive generations with *Mx1-Cre Rb^lox/lox^ p130^lox/lox^ p107^−/−^* to generate *Rb^lox/lox^ p130^lox/lox^ p107^−/+^ Foxn1^LacZ/+^* and *Rb^lox/lox^ p130^lox/lox^ p107^−/+^ Foxn1^LacZ/+^* with and without *Mx1-Cre*. As appropriate, mice were injected intraperitoneally with pI:pC at 3--8 wk of age. Thymi were removed from euthanized mice and processed as appropriate for the particular experiment.

### BM transplantation.

Chimeric mice were generated by lethal irradiation (9 Gr) of 3-mo-old *Mx1-Cre p107-Single* and control mice expressing only the Ly5.1 antigen. Irradiated mice were rescued by retroorbital transplantation of 2 × 10^6^ wild-type BM cells expressing both the Ly5.1 and Ly5.2 antigens. pI:pC was injected 12 wk after transplantation. Tissues were harvested 12--16 wk later.

### Immunofluorescence.

Immunofluorescence was performed on frozen sections or sections from paraffin-embedded tissues as described previously ([@bib12]; [@bib24]; [@bib6]; [@bib41]). Images were obtained by confocal microscopy using a confocal LSM 510 Meta (Carl Zeiss) with a Plan-Apochromat 20×/0.8 objective and analyzed with AxioVision 4.8 software (Carl Zeiss). Primary antibodies were directed against Foxn1 (goat anti--mouse, G-20; Santa Cruz Biotechnology, Inc.), K5 (rabbit anti--mouse; Covance), K8 (Troma-1; Developmental Studies Hybridoma Bank), K14 (rabbit anti--mouse; Covance), β5t (rabbit anti--mouse; MBL International Corporation), CD205 (rat biotinylated; Abcam), UEA-1--biotin (Vector Laboratories), CD31 (goat anti--mouse; BD), and PDGFR-β (goat anti--mouse; R&D Systems). Secondary antibodies included donkey anti--goat Cy5, donkey anti--rabbit 594, donkey anti--rat FITC, donkey anti--rabbit Texas Red, and streptavidin-FITC (Jackson ImmunoResearch Laboratories, Inc.) and donkey anti--goat Alexa Fluor 594 (Invitrogen).

### Histology.

Hematoxylin and eosin (H&E) staining was performed on paraffin-embedded sections. For H&E staining, thymi were fixed with 4% paraformaldehyde overnight, dehydrated in gradient ethanol solutions, and embedded in paraffin. 5--10-µm sections were cut and stained with H&E. Oil Red O staining was performed on frozen sections as follows: sections were fixed in 4% formalin for 10 min, washed with running water, rinsed in 60% isopropanol, stained for 15 min in fresh Oil Red O solution, washed in 60% isopropanol, stained briefly with hematoxylin, and washed with running water for 10 min. Microscopy was performed on a DM2000 microscope (Leica) at room temperature using a DFC500 camera (Leica). Images were analyzed using LASV3.8 software.

### Cytometry.

FACS analysis sorting was performed on an LSRI, Vantage, or FACs ARIA LSRII (BD). Data were acquired on CellQuest or FACSDiva (BD) and analyzed with FlowJo software (Tree Star). Antibodies for Kit, CD25, CD3ε, CD4, CD8, MHCII, CD40, CD205, CD80, CD45, Ly5.1, Ly5.2, Ly51, Mac1, Ter119, B220, Gr1, and Sca1 were purchased from eBioscience. FITC-conjugated UEA1 was purchased from Vector Laboratories. Cell cycle analysis was performed by intraperitoneal injection of BrdU, followed by euthanasia 1--4 h after injection. Cells were FACS sorted and analyzed for BrdU content as described previously ([@bib57]). TECs were isolated by enzymatic digestion. Thymi were cut into ∼1-mm^3^ pieces, and fragments were digested by a mixture of DNase I, and collagenase A/D:Dispase for 60 min at 37°C. Cells were passed through a 45-µm filter and washed in PBS/2% serum. Red cells were lysed using ammonium lysis buffer on ice. After three PBS/serum washes, cells were blocked in PBS/serum for 15 min. Suspensions were enriched for cells of interest by incubating with anti-MHCII PE or anti-EPCAM PE or biotin-conjugated antibodies, followed by incubation with anti-PE or antibiotin magnetic beads (Miltenyi Biotec) and passing over a MACS MS or LS column (Miltenyi Biotec). Cells were incubated for 30 min on ice with appropriate antibodies, washed, and resuspended for analysis in PBS/serum.

### Plasmids and sequence analysis.

Promoter sequence identification and alignment are as described on the University of California, Santa Cruz (UCSC) genome browser. The *Foxn1* promoter (from −1550 to 64) was cloned in pGL3 basic. Point mutations were introduced by subcloning a 129-bp fragment that spans from an *Xma1* site at −212 to the ECORV site at −83 and includes point mutations of the 2--3 E2F binding sites. E2F3- and RB-expressing plasmids have been described previously ([@bib2]; [@bib7]). Primer sequences are available upon request.

### ChIP.

ChIP analysis in TEC100, TEC71, and 210R cell lines (a gift from A. Farr, University of Washington, Seattle, WA) and RT--quantitative PCR (RT-qPCR) were performed as described in [@bib8]. Chromatin was sonicated using a fisher probe sonicator 30% output power for eight cycles of 30 s. The chromatin was precleared before being diluted and bound by 4 µg of the primary antibody overnight at 4°C. Each ChIP was then incubated with 8 µg rabbit anti--mouse IgG (MP Biomedicals) or anti--mouse p16 antibody (N-20; Santa Cruz Biotechnology, Inc.) as a secondary for 1 h. Nucleoprotein complexes were pulled down using Pansorbin cells (EMD Millipore). Complexes were digested with Proteinase K and RNase A and purified by a QIAquick PCR Purification kit (QIAGEN). Analysis was performed using qPCR with primers directed against Foxn1, Cyclin A, and GAPDH promoters (primer sequence available upon request) using SYBR-green reagents (Applied Biosystems). PCR was run on a C1000 thermal cycler (Bio-Rad Laboratories).

### Immunoblot analysis.

Protein lysates were prepared by Triton X-100--based lysis from TECs pooled according to age and genotype from 5--12 animals each. Equal amounts of protein were loaded onto either manually prepared 10% Bis-Tris gels or Novex NuPAGE 4--12% gradient gels (Invitrogen) and run until appropriate separation was achieved. Gels were transferred to polyvinylidene difluoride membrane (GE Healthcare). Blots were probed with primary antibodies anti-Tubulin (T9026; Sigma-Aldrich); anti-Foxn1 H-270, anti-Foxn1 G-20, anti-RB C-15, and anti-CCND1 H-295 (Santa Cruz Biotechnology, Inc.); pooled anti--phospho-RB S807/811 and S608 (Cell Signaling Technology); and anti-CDK4 (DCS-31; Invitrogen). HRP-conjugated secondary antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. Signal was detected using either ECL Western blotting reagent (Thermo Fisher Scientific) or ECL-Prime Western blot detection reagent (GE Healthcare).

### Cell culture, transfections, and luciferase analysis.

TEC lines (TEC100, TEC71, and 210R) were grown in RPMI 1640 or DMEM supplemented with 10% serum, glutamine, penicillin, and streptomycin. Transfections were performed using either Lipofectamine 2000 (Invitrogen) or Fugene (Promega) and included experimental plasmids with TK-Renilla (Promega) and pcDNA plasmid to ensure transfection of equivalent amounts of DNA. Luciferase assays were performed at least three times in triplicates using the Dual Luciferase Assay System (Promega) and analyzed using the Hybrid Synergy Reader and Gen5 V2.00 software (BioTek).

### Statistical analysis.

For analysis of two populations, statistical analyses were performed using a two-tailed paired Student's *t* test. A p-value of \<0.05 was required for significance (actual p-values are listed in figure legends). For analyses for three or more populations, significance was determined using ANOVA analysis.

### Online supplemental material.

Fig. S1 describes complex gating strategies used in this study. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20121716/DC1>.
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